Catalyst Pharmaceuticals News

Catalyst Pharmaceuticals Analyst Ratings

BenzingaJun 6 09:22

Catalyst Pharmaceuticals Analyst Ratings

BenzingaJun 3 05:26

HC Wainwright & Co. Reiterates Buy on Catalyst Pharmaceuticals, Maintains $26 Price Target

BenzingaJun 3 05:28

HC Wainwright & Co. : The Catalyst Pharmaceuticals (CPRX.US) rating was maintained, adjusted from buy to buy rating, and the target price was adjusted from $24.00 to $26.00.

Zhitong FinanceMay 10 07:20

Catalyst Pharmaceuticals Analyst Ratings

BenzingaMay 10 07:10

Catalyst Pharmaceuticals Analyst Ratings

BenzingaMar 27 06:30

Catalyst Pharmaceuticals Analyst Ratings

BenzingaMar 22 12:59

Catalyst Pharmaceuticals Analyst Ratings

BenzingaMar 14 07:01

Citigroup Initiates Coverage On Catalyst Pharmaceuticals With Buy Rating, Announces Price Target of $27

BenzingaMar 14 07:02

Catalyst Pharmaceuticals Analyst Ratings

BenzingaMar 7 09:58

BofA Securities Initiates Catalyst Pharmaceuticals With Buy Rating, Price Target Is $23

MT NewswiresMar 7 09:18

Catalyst Pharmaceuticals Analyst Ratings

BenzingaMar 1 05:36

Catalyst Pharmaceuticals Analyst Ratings

BenzingaDec 21, 2023 03:41

Cantor Fitzgerald Reiterates Overweight on Catalyst Pharmaceuticals, Maintains $27 Price Target

BenzingaAug 22, 2023 08:39

Catalyst Pharmaceuticals Analyst Ratings

BenzingaAug 22, 2023 08:38

HC Wainwright & Co. Reiterates Buy on Catalyst Pharmaceuticals, Maintains $24 Price Target

BenzingaAug 11, 2023 06:59

Catalyst Pharmaceuticals Analyst Ratings

BenzingaAug 11, 2023 06:58

HC Wainwright & Co. Reiterates Buy on Catalyst Pharmaceuticals, Maintains $24 Price Target

BenzingaJul 21, 2023 05:18

Catalyst Pharmaceuticals Analyst Ratings

BenzingaJul 21, 2023 05:18

Cantor Fitzgerald Reiterates Overweight on Catalyst Pharmaceuticals, Maintains $25 Price Target

BenzingaJun 21, 2023 08:59